1622189-43-8
Chemical Structure
Nogapendekin alfa (his tag)
Synonym(s): IL-15N72D
- CAS No.: 1622189-43-8
- Formula:N/A
- Molecular Weight:(13.91 kDa)
IUPAC Name: (2R,3R,4S,5R,6R)-6-((benzoyloxy)methyl)-5-hydroxy-2-(1H-indol-1-yl)-4-(phosphonooxy)tetrahydro-2H-pyran-3-yl 2-aminobenzoate
SMILES: [Nogapendekin alfa (his tag)]
Biological Activity: Nogapendekin alfa his tag is an immunostimulant that binds to the IL-2RβγC complex on immune cells. Nogapendekin alfa his tag stimulates the proliferation and activation of natural killer cells and CD8+ T cells, upregulates the expression of granzyme B and perforin, and activates the innate and adaptive immune branches. Nogapendekin alfa his tag forms ALT-803 with IL-15RαSuFc; this complex has an extended biological half-life, improved biodistribution and retention in lymphoid tissues, enhances natural killer cell-mediated rituximab-dependent cellular cytotoxicity, and reduces tumor burden and improves survival when combined with anti-CD20 monoclonal antibody therapy. Nogapendekin alfa his tag can be used in the research of non-Hodgkin's lymphoma[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nogapendekin alfa (his tag) | 98.62% | Nogapendekin alfa his tag is an immunostimulant that binds to the IL-2RβγC complex on immune cells. Nogapendekin alfa his tag stimulates the proliferation and activation of natural killer cells and CD8+ T cells, upregulates the expression of granzyme B and perforin, and activates the innate and adaptive immune branches. Nogapendekin alfa his tag forms ALT-803 with IL-15RαSuFc; this complex has an extended biological half-life, improved biodistribution and retention in lymphoid tissues, enhances natural killer cell-mediated rituximab-dependent cellular cytotoxicity, and reduces tumor burden and improves survival when combined with anti-CD20 monoclonal antibody therapy. Nogapendekin alfa his tag can be used in the research of non-Hodgkin's lymphoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
